bisbenzimidazole has been researched along with Osteosarcoma in 1 studies
Bisbenzimidazole: A benzimidazole antifilarial agent; it is fluorescent when it binds to certain nucleotides in DNA, thus providing a tool for the study of DNA replication; it also interferes with mitosis.
Osteosarcoma: A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Indovina, P | 1 |
| Rainaldi, G | 1 |
| Santini, MT | 1 |
1 other study available for bisbenzimidazole and Osteosarcoma
| Article | Year |
|---|---|
Three-dimensional cell organization leads to a different type of ionizing radiation-induced cell death: MG-63 monolayer cells undergo mitotic catastrophe while spheroids die of apoptosis.
Topics: Amino Acid Chloromethyl Ketones; Apoptosis; bcl-2-Associated X Protein; Bisbenzimidazole; Blotting, | 2007 |